HDAC9 and ovarian carcinoma: All HDAC inhibitors examined in this study (R306465, vorinostat, panobinostat and TSA) showed comparable potency towards both catalytic domains of cellular HDAC6, since tubulin acetylation and inhibition of Hsp90 function were observed at similar concentrations in A2780 ovarian carcinoma cells.